Apyx Medical Corporation
2.9500-0.15 (-4.84%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · APYX · USD
Key Stats
Market Cap
111.57MP/E (TTM)
-Basic EPS (TTM)
-0.44Dividend Yield
0%Recent Filings
8-K
Apyx approves board, auditors
Apyx Medical Corporation's stockholders approved all key proposals at the August 7, 2025, annual meeting, electing directors Stavros G. Vizirgianakis, Charles D. Goodwin, Lawrence J. Waldman, Minnie Baylor-Henry, and Wendy Levine to serve until 2026. They ratified RSM US LLP as auditors for the year ending December 31, 2025, endorsed executive compensation, and favored annual say-on-pay votes. The board gained flexibility by amending the certificate to omit Article EIGHTH. Governance streamlined.
10-Q
Q2 FY2025 results
Apyx Medical's Q2 revenue dipped 6.4% year-over-year to $11.4M, with Advanced Energy holding steady at $9.7M while OEM fell 28.5% to $1.7M, yet gross margins edged up to 62.3% from better segment mix. Operating loss narrowed sharply to $2.6M from $5.5M, thanks to 42% cuts in R&D and 34% in salaries after last year's workforce trim. Diluted EPS improved to -$0.09 from -$0.19, confirmed against 40.7M weighted shares with anti-dilution from options and warrants. Cash stood at $29.3M with $34.4M in term debt at 12% under amended covenants met so far; free cash flow not disclosed in the 10-Q. FDA-cleared AYON launches this half, eyeing body contouring tailwinds. Product liability suits loom as a key risk.
8-K
Apyx Q2 revenue dips, guidance rises
Apyx Medical reported Q2 2025 revenue of $11.4 million, down 6.4% from $12.1 million last year, yet slashed net loss to $3.8 million from $6.6 million through $3.4 million in operating expense cuts. The company launched AYON Body Contouring System post-FDA clearance, sparking strong demand and initial U.S. placements, while kicking off Renuvion sales in China amid rising aesthetic needs. It raised FY2025 revenue guidance to $50.0-$52.0 million. Losses narrowed sharply.
8-K
FDA clears AYON system
Apyx Medical Corporation secured FDA 510(k) clearance for its AYON Body Contouring System on May 13, 2025, marking the first all-in-one platform integrating fat removal, tissue contraction via Renuvion, and electrosurgical tools for aesthetic procedures. The company plans a commercial launch to key opinion leader surgeons in critical geographies during the second half of 2025, targeting rising demand from GLP-1 drug users seeking skin laxity solutions. AYON streamlines surgeries while boosting precision. Yet regulatory expansions for power liposuction remain pending.
10-Q
Q1 FY2025 results
Apyx Medical's Q1 revenue dipped 7.9% y/y to $9.4M, with Advanced Energy up 5.8% to $7.9M on stronger domestic handpiece sales, while OEM fell 44.7% to $1.5M from lower volumes. Gross margin expanded to 60.1% from 58.1%, yet operating loss narrowed to $3.1M from $6.6M, driven by 34.4% lower salaries and 42.4% reduced R&D after workforce cuts. Net loss improved to $4.2M ($0.10 per diluted share) from $7.6M ($0.22), with EPS aligning to 40.7M weighted shares; the gap from operating loss ties to $1.4M interest expense. Cash held steady at $31.0M, with $0.7M operating outflow versus $6.3M last year, backed by $34.1M net debt under amended covenants targeting $37.0M Advanced Energy revenue for 2025. AYON's FDA submission eyes H1 clearance. Product liability suits loom as a key risk.
AEMD
Aethlon Medical, Inc.
5.75+0.32
AERG
Applied Energetics, Inc.
1.72-0.01
AMIX
Autonomix Medical, Inc.
1.05-0.04
BDMD
Baird Medical Investment Holdin
1.44+0.02
BSX
Boston Scientific Corporation
100.30-0.67
CNMD
CONMED Corporation
46.71-0.61
ENOV
Enovis Corporation
31.99-0.87
NVNO
enVVeno Medical Corporation
0.72+0.00
OFIX
Orthofix Medical Inc.
15.32-0.70
VYCO
Vycor Medical, Inc.
0.15+0.00